- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04440670
Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Preterm Neonates
Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Preterm Neonates: a Placebo-controlled Randomized Multicenter Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design and settings:
This present study will be a randomized, placebo-controlled, double-blinded, multi-center trial to be conducted at 12 medical centers in tertiary hospitals with Neonatal Intensive Care Unit that were selected by the expert committee. A total of 140 neonates fulfilling the eligibility criteria will be enrolled. Subsequently, the participants will be randomly divided into two groups (ACBMNC infusion group and control (placebo) group ) in a ratio of 1:1.
Sample size:
Based on our previous study and others' study, we found the ACBMNC infusion was effective in reducing respiratory support duration in preterm infants. The rate of BPD among extremely preterm infants in our NICU was 60% (pA). What we expect to be an intended (or at least acceptable) effect of the ACBMNC infusion is 25 % reduction in frequency of BPD(pB:35%). To detect this difference with a sensitivity of 80% and an error probability of 5%, at least 59 patients per randomization group will be required using the following formula:
n=(pA(1-pA)/κ+pB(1-pB))((z1-α/2+z1-β)/(pA-pB))2 To account for the possibility of as high as 20% loss to follow-up, our estimated sample size is 140 cases totally.
Objectives:
Primary objective: The primary objective of this trial is to evaluate the efficacy of ACBMNC infusion in preventing bronchopulmonary dysplasia or death at 36 weeks of postmenstrual age or discharge home in extremely preterm infants.
Secondary objectives:
- To compare the mortality rate at 36 weeks of postmenstrual age.
- To compare the BPD severity
- To compare the rate of other common preterm complications included intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), respiratory distress syndrome (RDS), ventilation-associated pneumonia (VAP), hypoxic ischemic encephalopathy (HIE), late onset sepsis (LOS) and anemia.To compare the duration of mechanical ventilation and oxygen therapy in two groups
- To determine re-intubation rate and time return to BW
- To compare the duration of antibiotic usage
- To determine the long term outcomes after two years follow up
Participants:
Inclusion criteria:
Infants fulfilling all the following inclusion criteria will be enrolled in this trial: 1. born at study hospital; 2. singleton birth; 3. less than 28 weeks GA 4.Signed informed consent obtained; 5. had available umbilical cord blood (UCB).
Exclusion criteria:
Those infants are excluded if they were 1. with severe congenital abnormalities; 2.with maternal clinical chorioamnionitis 3. the mother was positive for hepatitis B (HBsAg and/or HBeAg) or C virus (anti-HCV), syphilis, HIV (anti-HIV-1 and -2) or IgM against cytomegalovirus, rubella, toxoplasma and herpes simplex virus.
Trial treatment methods:
Soon after the preterm infant was deliveried, written consent was signed by the parents, and autologous cord blood infusion was applied to the baby in addition to routine pulmonary surfactant replacement, and mechanical ventilation support as indicated. Those assigned to the ACBMNC group received an infusion of ACBMNC with 24 h after birth. Those in control group received an infusion of a placebo solution which is normal saline with the same volume. Cell dose for all patients was targeted at 5×107 cells per kilogram.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: zhuxiao Ren, MD
- Phone Number: +8613538984634
- Email: renzhx1990@163.com
Study Locations
-
-
Guangdong
-
Dongguan, Guangdong, China
- Recruiting
- Ren Xuejun
-
Contact:
- Ren Xuejun, MD
-
Guangzhou, Guangdong, China, 511442
- Recruiting
- Jie Yang
-
Contact:
- Jie Yang, PHD
- Phone Number: 020 39151777
- Email: jieyang@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Infants fulfilling all the following inclusion criteria will be enrolled in this trial: 1. born at study hospital; 2. singleton birth; 3. less than 28 weeks GA 4.Signed informed consent obtained; 5. had available umbilical cord blood (UCB).
Exclusion Criteria:
Those infants are excluded if they were 1. with severe congenital abnormalities; 2.with maternal clinical chorioamnionitis 3. the mother was positive for hepatitis B (HBsAg and/or HBeAg) or C virus (anti-HCV), syphilis, HIV (anti-HIV-1 and -2) or IgM against cytomegalovirus, rubella, toxoplasma and herpes simplex virus.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ACBMNC infusion group
Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion within 24 h after birth.
Cell dose for all patients was targeted at 5×107 cells per kilogram.
|
preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth
|
Placebo Comparator: control group
Those in control group will receive an infusion of a placebo solution which is normal saline with the same volume.
|
preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
frequency of bronchopulmonary dysplasia or death
Time Frame: 36 weeks of postmenstrual age or discharge home whichever comes first.
|
The frequency of bronchopulmonary dysplasia or death at 36 weeks of postmenstrual age or discharge home whichever comes first.
|
36 weeks of postmenstrual age or discharge home whichever comes first.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mortality
Time Frame: 36 weeks of postmenstrual age or the discharge
|
The mortality rate.
|
36 weeks of postmenstrual age or the discharge
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Jie Yang, Guangdong Women and Children Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Guang dong W C H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BPD
-
Universitat Jaume IHospital de la RiberaNot yet recruitingBorderline Personality Disorder (BPD)Spain
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingBorderline Personality Disorders | BPDSpain
-
University of OldenburgProf. René Hurlemann; Jella Voelter, M.Sc.RecruitingBorderline Personality Disorder (BPD)Germany
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
NHS Greater Glasgow and ClydeUnknownBorderline Personality Disorder (BPD) | Antisocial Personality Disorder (ASPD)United Kingdom
-
AbbVieRecruitingHealthy Volunteers | Generalized Anxiety Disorder (GAD) | Bipolar Disorder (BPD)United States
-
ArkinAmsterdam UMC, location VUmc; Ziekenhuis Amstelland; Meander Medisch Centrum; Sinai... and other collaboratorsRecruitingPosttraumatic Stress Disorder (PTSD) | Borderline Personality Disorder (BPD)Netherlands
-
Sheba Medical CenterNot yet recruitingThe Relationship Between Oral Vitamin A Administration and the Incidence of BPD in Preterm Infants Born Before Week 29 of Pregnancy
-
Karolinska InstitutetThe Swedish Research Council; Göteborg University; University of California,... and other collaboratorsActive, not recruitingPremature Birth- and BPD-related Obstructive Lung DiseaseSweden
-
Adel MohamedHealth Sciences Centre, Winnipeg, Manitoba; Mount Sinai Hospital, CanadaCompletedBronchopulmonary Dysplasia (BPD)Canada
Clinical Trials on autologous cord blood mononuclear cells
-
Murdoch Childrens Research InstituteCompletedHeart Defects, Congenital | Hypoplastic Left Heart Syndrome | Pediatric DisorderAustralia
-
Guangdong Women and Children HospitalNot yet recruiting
-
yangjieCompletedSafety Issues | Neonatal Death | BPD - Bronchopulmonary DysplasiaChina
-
Guangdong Women and Children HospitalCompletedBronchopulmonary Dysplasia | Premature | Neonatal DeathChina
-
Guangdong Women and Children HospitalRecruitingSafety Issues;Effect of DrugsChina
-
Aryn KnightM.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaboratorsWithdrawn
-
Guangdong Women and Children HospitalUnknownSafety Issues | Effect of DrugsChina
-
Timothy J Nelson, MD, PhDMayo Clinic; Children's Hospital of Philadelphia; Children's Hospital Colorado; University of Oklahoma and other collaboratorsCompletedHypoplastic Left Heart SyndromeUnited States
-
Guangdong Women and Children HospitalRecruitingPreterm Infants | Nutrition | Growth and Development | Neonatal Necrotizing EnterocolitisChina
-
Guangdong Women and Children HospitalUnknownSafety Issues | Neonatal Death | Effect of DrugsChina